Because LCMT1 is a specific SAM-dependent methyltransferase, it is tempting to speculate that an increase in the cellular SAH after the treatment of breast cancer cells with TMCG/DIPY may also result in the inhibition of PP2A assembly. The gene discussed is LCMT1; the disease is breast carcinoma.